LEADER 04247nam 2201441z- 450 001 9910566473703321 005 20231214132932.0 035 $a(CKB)5680000000037643 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81202 035 $a(EXLCZ)995680000000037643 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMolecular Pathways in Cancers 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (284 p.) 311 $a3-0365-3682-5 311 $a3-0365-3681-7 330 $aThis book includes some recent works providing the readers with novel relevant findings about the main signaling pathways that govern the molecular pathogenesis of some of the highest prevalent human tumors, which are the basis for developing alternative therapeutic strategies to improve patient outcomes. 606 $aMedicine$2bicssc 606 $aOncology$2bicssc 610 $aactin cytoskeletal reorganization 610 $abreast cancer 610 $aCD99 agonist 610 $aEGFR dimerization 610 $aendocytosis 610 $aFAK dephosphorylation 610 $aPTPN12 610 $aRac1 610 $aRhoA 610 $atripeptide 610 $aOMD 610 $aPRELP 610 $atumor suppression gene 610 $abladder cancer initiation 610 $atight junction 610 $apartial EMT 610 $atousled-like kinase (TLK) 610 $aNIMA-related kinase 1 (NEK1) 610 $ayes-associated protein 1 (YAP1) 610 $athioridazine (THD) 610 $aMS-determined phosphopeptides 610 $ahuman immunodeficiency virus type 1 610 $aepithelial cells 610 $acarcinogenicity 610 $aoxidative stress 610 $areactive oxygen species 610 $agp120 610 $aTat 610 $aNef 610 $amatrix protein p17 610 $areverse transcriptase 610 $amitochondria 610 $ametastasis 610 $aOXPHOS 610 $acancer 610 $aWarburg effect 610 $acancer therapeutics 610 $amyeloproliferative neoplasms 610 $asignaling pathways 610 $aJAK2 610 $aCALR 610 $aMPL 610 $aTPOR 610 $aDUSP1 610 $aMAPK 610 $aSnail 610 $aprostate cancer 610 $amigration and invasion 610 $apatient survival 610 $abiomarkers 610 $apBRD4 610 $aSET 610 $aPP2A 610 $aprognosis 610 $atriple negative breast cancer 610 $aresistance 610 $aanti-receptor therapy 610 $atrastuzumab 610 $aPI3K 610 $amTOR 610 $aTAK-228 610 $aepigenetic 610 $amethylation 610 $aacetylation 610 $anon-coding RNA 610 $asmall-cell lung cancer 610 $atriple-negative breast cancer 610 $apancreatic ductal adenocarcinoma 610 $aglioblastoma 610 $ametastatic melanoma 610 $aadvanced ovarian cancer 610 $ahepatocellular carcinoma 610 $aimmune evasion 610 $aimmunotherapy 610 $aimmune checkpoint inhibitors 610 $aoncogenic signaling pathway 610 $amolecular targeted agents 610 $agenome 610 $aepigenome 610 $atumor immune microenvironment 610 $aovarian cancer 610 $aadaptive immunity 610 $ainnate immunity 610 $acomplement system 610 $acancer immunology 610 $atumor microenvironment 610 $asplicing pathway 610 $aluminal breast cancer 610 $aBET inhibitors 615 7$aMedicine 615 7$aOncology 700 $aCristo?bal$b Ion$4edt$01309570 702 $aRodri?guez$b Marta$4edt 702 $aCristo?bal$b Ion$4oth 702 $aRodri?guez$b Marta$4oth 906 $aBOOK 912 $a9910566473703321 996 $aMolecular Pathways in Cancers$93029401 997 $aUNINA